On August 25, 2021 Patrys reported its Annual Report for the 2020-2021 Financial Year (FY21) (Press release, Patrys, AUG 25, 2021, View Source [SID1234586882]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights include:

2020

Expansion of deoxymab portfolio with the addition of full sized IgG antibody, PAT-DX3
First patent granted for deoxymab-nanoparticles
Capital raising of $7.3m via a Placement and Rights Issue
2021

Successful development and selection of an optimised stable cell-line for commercial scale production of clinical grade PAT-DX1
New United States patent granted for Patrys’ deoxymab assets
Completion of animal pharmacokinetic studies for both PAT-DX1 antibody fragment and full-sized PAT-DX3 IgG antibody
Announcement of a collaborative research program with Imagion Biosystems Limited to improve brain tumor imaging and diagnosis
Publication of preclinical data, from collaboration with Yale School of Medicine demonstrating the ability of PAT-DX1 to cross the blood-brain barrier (BBB) and significantly inhibit the growth of both primary and secondary cancers in the brain in animal models